Issue 37

New Therapies, New Challenges: Experts Weigh In on Next-Gen Therapy Development

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Unlocking the Potential of Next-Gen Therapies with Advanced Technology

Novel therapeutic modalities, such as cell, gene, and nucleic acid therapies, are offering more effective, personalized treatment options to patients with chronic and/or rare diseases that were, not too long ago, considered to be untreatable. The latest regulatory data (at the time of writing) confirm that approvals of these therapies have generally increased year-over-year, with 45 cell and gene therapy (CGT) products approved by FDA and 27 advanced therapy medicinal products (eight of which have been withdrawn or not renewed) approved by EMA since the noughties.

Read more here.

FEATURED STORIES

Rising Rates of Measles are Highlighting Level of Vaccine Misinformation

Read more here.

Bora Adds Small-Scale Isolator Line to Baltimore Facility

Read more here.

Sanofi Enters into Agreement to Acquire Blueprint Medicines

Read more here.

Syntegon Unveils New Aseptic Filling Line

Read more here.

Dicot Pharma Unveils MoA Findings for Potency Therapy

Read more here.

Moderna Gains FDA Approval for New Coronavirus Vaccine

Read more here.